Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Electron Transport Chain: Complex I and II

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...

Drugs that Stabilize Microtubules

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluation of Active and Passive Targeting Drug Delivery Systems as a Mechanism to Improve the Anticancer Potential of Titanium(IV).

ChemMedChem·2026

Same author

Towards a dual copper(II) and iron(III) transmetalation strategy for an anticancer application with the deferasirox chelator.

Journal of inorganic biochemistry·2026

Same author

Ligand-Based Redox Chemistry and Anti-Kasha Fluorescence in Silver(I) Tripyrrindione Radical.

Inorganic chemistry·2026

Same author

Detection of a clamp-shaped conformation of a neuronal nitric oxide synthase construct by pulsed EPR.

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry·2025

Same author

Disulfide-based 2-pyridyl-hydrazone prochelators induce iron deprivation and oxidative stress in ovarian cancer cells.

Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry·2025

Same author

Elucidating the High Affinity Copper(II) Complexation by the Iron Chelator Deferasirox Provides Therapeutic and Toxicity Insight.

ChemMedChem·2024

Same journal

DeepDOX1: A Dual-Drive Framework Integrating Deep Learning and First-Principles Quantum Chemistry for Drug-Protein Affinity Prediction.

JACS Au·2026

Same journal

Catalyst-Controlled Regiodivergent C-H Olefination of Furanyl Carbamates through a Rational Approach.

JACS Au·2026

Same journal

Charting the Biosynthetic Landscape of Hybrid Polyketide-Nonribosomal Peptide-Specialized Lipids.

JACS Au·2026

Same journal

Valence-State-Dependent Surface Lattice Oxygen in CeO<sub>2</sub>‑Modified VPO Catalysts: Elucidating the Mechanism of <i>n</i>‑Butane Selective Oxidation to Maleic Anhydride.

JACS Au·2026

Same journal

Quantitative Insights into Pressure-Dependent Mass Transport and Reaction Kinetics in Electrochemical CO<sub>2</sub> Reduction.

JACS Au·2026

Same journal

3‑Methylthiopropionic Acid Kills Carbapenem-Resistant <i>Klebsiella pneumoniae</i> by Disrupting Membrane Integrity and Bioenergetics.

JACS Au·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 7, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

DefNEtTrp: An Iron Dual Chelator Approach for Anticancer Application.

Israel Rodríguez¹, Carmen Acosta¹, Christopher Nieves-Escobar¹

¹Department of Chemistry, University of Puerto Rico, Río Piedras Campus, Río Piedras, Puerto Rico 00931, United States.

|December 30, 2024

Summary

This summary is machine-generated.

A novel dual iron chelator, DefNEtTrp, effectively targets cancer by disrupting iron metabolism. This new compound shows superior anticancer activity and induces cell death through apoptosis and ferroptosis.

More Related Videos

Biofunctionalization of Magnetic Nanomaterials

Biofunctionalization of Magnetic Nanomaterials

Published on: July 16, 2020

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

Related Experiment Videos

Last Updated: May 7, 2026

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

Biofunctionalization of Magnetic Nanomaterials

Biofunctionalization of Magnetic Nanomaterials

Published on: July 16, 2020

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Author Spotlight: Assessing the Impact of Novel Iron Chelators on Cancer Cell Metabolism

Published on: February 23, 2024

Area of Science:

Biochemistry and Molecular Biology
Cancer Therapeutics
Medicinal Chemistry

Background:

Targeting iron metabolism is a novel strategy for cancer treatment.
Iron chelators like deferasirox (Def) and triapine (Trp) inhibit Fe-dependent pathways crucial for cancer cell proliferation and metastasis.
Triapine (Trp) specifically inactivates iron-dependent ribonucleotide reductase (RNR), essential for DNA replication.

Purpose of the Study:

To develop a novel dual iron chelator, DefNEtTrp, combining Def and Trp moieties.
To exploit the high affinity Fe(II/III) binding and redox modulation capabilities of Def and Trp.
To evaluate the anticancer potential of DefNEtTrp against various cancer cell lines.

Main Methods:

UV-vis spectroscopy, EPR spectroscopy, ESI and MALDI-TOF mass spectrometry, and cyclic voltammetry were used for characterization.
Antiproliferative activity was assessed using cytotoxicity assays (IC50).
Cell death mechanisms, including apoptosis and ferroptosis, were investigated.

Main Results:

DefNEtTrp demonstrated potent and broad-spectrum antiproliferative activity across different cancer cell lines.
The dual chelator exhibited superior cytotoxicity (IC50 0.77 ± 0.06 μM) compared to Def (2.6 ± 0.15 μM) and Trp (1.1 ± 0.04 μM).
DefNEtTrp selectively targeted cancer cells and induced cell death via both apoptosis and ferroptosis.

Conclusions:

DefNEtTrp is a promising dual iron chelator with significant anticancer properties.
The compound effectively disrupts cancer cell iron metabolism, leading to potent cytotoxicity.
DefNEtTrp represents a potential new therapeutic agent for broad-spectrum cancer treatment.